Federal Register / Vol. 74, No. 131 / Friday, July 10, 2009 / Notices 33267 

By September 21, 2009, FDA will post 

the following information: 

• Workshop agenda; 

• FDA Issues Paper that describes 

past history, current challenges, and 

possible approaches to improve the 

current system; 

• A series of prototypes that explore 

different written approaches to 

conveying prescription drug 

information to consumers; and 

• A list of FDA speakers, invited 

workshop participants, and meeting 

registrants. 

This public workshop is intended to 

explore potential approaches that will 

result in written prescription drug 

information that is comprehensible, 

accurate, and more easily accessible to 

consumers. The purpose of this public 

workshop is to assemble stakeholder 

groups to determine appropriate steps 

towards improving the content, format, 

distribution, and evaluation of patient 

information. 

Registration: To register for the 

meeting either: (1) Mail your registration 

information to one of the contact 

persons (see FOR FURTHER INFORMATION

CONTACT) or (2) e-mail your registration 

information to 

PatientInfoPublicWkshp@fda.hhs.gov. 

Registration information should include 

registrant name, company or 

organization, address, phone number, 

and e-address. Registration requests 

should be received by August 17, 2009. 

Registration is free. Seats are limited. 

FDA may limit the numbers of 

participants from each organization 

based on space limitations. Registrants 

will receive confirmation once they 

have been accepted for participation in 

the workshop. Onsite registration on the 

day of the meeting will be based on 

space availability on the day of the 

event starting at 7:30 a.m. If registration 

reaches maximum capacity, FDA will 

post a notice closing meeting 

registration for the workshop at http:// 

www.fda.gov/Drugs/NewsEvents/ 

ucm168106.htm. If you need special 

accommodations due to a disability, 

please contact Mary Gross or Marsha 

Holloman (see FOR FURTHER INFORMATION

CONTACT) at least 7 days in advance. 

Dated:July 2, 2009. 

Jeffrey Shuren, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E9–16335 Filed 7–9–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, NIDA 

ARRA Go Applications on Genetics, 

Harmonizing Phenotypes and Envirotypes, 

Epigenetics and Pharmacogenomics. 

Date: July 16, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Plaza Hotel, 10 Thomas 

Circle, NW., Washington, DC 20005. 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Blvd., Bethesda, MD 

20892–8401, 301–402–6626, 

gm145a@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, ARRA 

GO Criminal Justice Grant Application 

Review. 

Date: July 23, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Blvd., Bethesda, MD 

20892–8401, 301–402–6626, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, ARRA 

GO CTN-Based Grant Application Review. 

Date: July 27, 2009. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852. 

Contact Person: Mark R. Green, PhD, 

Deputy Director, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

435–1431, mgreen1@nida.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, ARRA 

GO Small Molecule and Vaccine 

Medications. 

Date: July 28, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sofitel Washington DC, Lafayette 

Hotel, 806 15th Street, NW., Washington, DC 

20005. 

Contact Person: Jose F Ruiz, PhD, 

Scientific Review Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, 6101 Executive Blvd., Rm. 

213, MSC 8401, Bethesda, MD 20892, 301– 

451–3086, ruizjf@nida.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, NIDA 

Conference Grant Application Review. 

Date: July 30, 2009. 

Time: 10 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852 

(Virtual Meeting). 

Contact Person: Mark R. Green, PhD, 

Deputy Director, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, 

(301)435–1431, mgreen1@nida.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, ARRA 

Grand Opportunities: Prevention 

Infrastructure. 

Date: August 4, 2009. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Dupont Hotel, 1500 New 

Hampshire Avenue, NW., Washington, DC 

20036. 

Contact Person: Nadine Rogers, PhD, 

Scientific Review Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Boulevard, Bethesda, 

MD 20892–8401, 301–402–2105, 

rogersn2@nida.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 91279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: July 1, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–16067 Filed 7–9–09; 8:45 am] 

BILLING CODE 4140–01–M 


sroberts on DSKD5P82C1PROD with NOTICES